-
Bridgebio asks FDA to approve potential 1st treatment for LGMD2i
Bridgebio Pharma has submitted an application asking the U.S. Food and Drug Administration (FDA) to
-
Simply Stated: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which the immune system








